Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Inclusion Criteria: * Participants ≥ 18 years of age. * Documented diagnosis of no del(5q) MDS that meets lower-risk Myelodysplastic Syndromes (MDS) classification. (Diagnosis criteria and risk classification criteria are based on clinical practice) * Patients who were erythropoiesis-stimulating agent (ESA)-naïve have received luspatercept monotherapy at least 2 cycles regardless of RS status. * Historical documentation of anemia before luspatercept treatment. Exclusion Criteria: * Had a history of acute myeloid leukemia (AML) prior to MDS diagnosis. * Received stem cell transplant prior to luspatercept treatment initiation.